Direct Biologics Granted FDA Approval of Third IND Application for the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy Extracellular vesicle product ExoFlo clinical trials to address early stage COVID-19. AUSTIN, Texas, June 29, 2021 (Newswire.com) Direct Biologics, a market-leading innovator and cGMP manufacturer of regenerative biologic products, announced today that the U.S Food and… Read More »Direct Biologics Granted FDA Approval for Third IND Application to Investigate the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy

The post Direct Biologics Granted FDA Approval for Third IND Application to Investigate the use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy appeared first on Direct Biologics.